QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares

Bulletin Express07-17

Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor share repurchase under Hong Kong’s Main Board Rule 13.25A for 17 July 2026. The company acquired 1,000 H-shares on the Stock Exchange at a single price of HK$15.99 per share, spending HK$0.02 million in aggregate.

Following the transaction, the number of issued shares (excluding treasury shares) eased to 223.37 million, down by 0.00045%. Treasury shares increased to 3.70 million, maintaining the total issued share capital at 227.07 million.

The repurchase forms part of the mandate approved on 29 May 2026, which allows QYUNS-B to buy back up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.99 million shares, representing 0.44% of the shares outstanding at the mandate date.

In line with Hong Kong listing regulations, QYUNS-B is restricted from issuing new shares or disposing of treasury shares until 16 August 2026. The company confirmed that the repurchase complied with all Main Board requirements and that no material changes have occurred in the previously filed explanatory statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1139831720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 18:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139831720","market":"hk","top_or_hot":-1,"title":"QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares","media":"Bulletin Express","content":"<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor share repurchase under Hong Kong’s Main Board Rule 13.25A for 17 July 2026. The company acquired 1,000 H-shares on the Stock Exchange at a single price of HK$15.99 per share, spending HK$0.02 million in aggregate.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) eased to 223.37 million, down by 0.00045%. Treasury shares increased to 3.70 million, maintaining the total issued share capital at 227.07 million.</p>\n<p>The repurchase forms part of the mandate approved on 29 May 2026, which allows QYUNS-B to buy back up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.99 million shares, representing 0.44% of the shares outstanding at the mandate date.</p>\n<p>In line with Hong Kong listing regulations, QYUNS-B is restricted from issuing new shares or disposing of treasury shares until 16 August 2026. The company confirmed that the repurchase complied with all Main Board requirements and that no material changes have occurred in the previously filed explanatory statement.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>QYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQYUNS-B Executes HK$15.99 On-Market Buyback; Issued Float Dips to 223.37 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-17 18:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor share repurchase under Hong Kong’s Main Board Rule 13.25A for 17 July 2026. The company acquired 1,000 H-shares on the Stock Exchange at a single price of HK$15.99 per share, spending HK$0.02 million in aggregate.</p>\n<p>Following the transaction, the number of issued shares (excluding treasury shares) eased to 223.37 million, down by 0.00045%. Treasury shares increased to 3.70 million, maintaining the total issued share capital at 227.07 million.</p>\n<p>The repurchase forms part of the mandate approved on 29 May 2026, which allows QYUNS-B to buy back up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.99 million shares, representing 0.44% of the shares outstanding at the mandate date.</p>\n<p>In line with Hong Kong listing regulations, QYUNS-B is restricted from issuing new shares or disposing of treasury shares until 16 August 2026. The company confirmed that the repurchase complied with all Main Board requirements and that no material changes have occurred in the previously filed explanatory statement.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02509","symbol_name":"荃信生物-B","start_time":0,"source_url":"","article_id":"1139831720","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139831720","pubTimestamp":1784282612,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor share repurchase under Hong Kong’s Main Board Rule 13.25A for 17 July 2026. The company acquired 1,000 H-shares on the Stock Exchange at a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02509":"荃信生物-B"},"translate_title":"QYUNS-B执行15.99港元场内回购；已发行流通量降至 2.2337 亿股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1},"content_text":"Qyuns Therapeutics Co., Ltd. (QYUNS-B) disclosed a minor share repurchase under Hong Kong’s Main Board Rule 13.25A for 17 July 2026. The company acquired 1,000 H-shares on the Stock Exchange at a single price of HK$15.99 per share, spending HK$0.02 million in aggregate.\nFollowing the transaction, the number of issued shares (excluding treasury shares) eased to 223.37 million, down by 0.00045%. Treasury shares increased to 3.70 million, maintaining the total issued share capital at 227.07 million.\nThe repurchase forms part of the mandate approved on 29 May 2026, which allows QYUNS-B to buy back up to 22.44 million shares. Cumulative purchases under this mandate now stand at 0.99 million shares, representing 0.44% of the shares outstanding at the mandate date.\nIn line with Hong Kong listing regulations, QYUNS-B is restricted from issuing new shares or disposing of treasury shares until 16 August 2026. The company confirmed that the repurchase complied with all Main Board requirements and that no material changes have occurred in the previously filed explanatory statement.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1139831720","isCrawlerRequest":true}